Valbiotis SAS
Research Valbiotis SAS (ALVAL) on Bullrun: market cap EUR 19.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALVAL
- ExchangePA
- CountryFrance
- SectorConsumer Defensive
- IndustryPackaged Foods
- CurrencyEUR
- Market capEUR 19.16M
- Financial periodFY2025
- RevenueEUR 905.00K
- Revenue growth417.1%
- Net income-EUR 9.42M
- Free cash flow-EUR 8.19M
- Gross margin-146.2%
Valuation Snapshot
latest market cap is EUR 19.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 905.00K | -EUR 9.42M | -EUR 8.19M | -146.2% | -0.47 | EUR 8.68M | EUR 5.09M | EUR 6.96M |
| FY2024 | EUR 175.00K | -EUR 10.03M | -EUR 11.80M | -1396.0% | -0.63 | EUR 11.58M | EUR 5.72M | EUR 10.37M |
| FY2023 | EUR 4.73M | -EUR 7.37M | -EUR 8.30M | 56.4% | -0.59 | EUR 25.02M | EUR 6.88M | EUR 19.60M |
| FY2022 | EUR 785.00K | -EUR 12.31M | -EUR 9.48M | 97.7% | -1.2 | EUR 20.83M | EUR 7.18M | EUR 13.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 19.16M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure;
Related stock research
Other Consumer Defensive stocks
Frequently asked questions
What is Valbiotis SAS's market cap?
Valbiotis SAS's market capitalization is EUR 19.16M.
What does Valbiotis SAS do?
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis.